Relief Therapeutics Plans Merger With NeuroX Creating AI Neurotech Platform

Relief Therapeutics Holding SA has announced a proposed business combination with NeuroX Group SA, which recently acquired the assets and operations of MindMaze, a leader in digital neurotherapeutics. The merger aims to create a publicly listed, AI-driven health tech company that integrates software-delivered, disease-modifying clinical interventions with pharmacological treatments to improve neurological disease care. NeuroX is valued at CHF 1 billion, significantly higher than Relief’s CHF 100 million valuation, with NeuroX shareholders set to own 91% of the combined entity and Relief shareholders the remaining 9%. The shares of the combined company will continue trading on the SIX Swiss Exchange, with the definitive transaction agreement expected in Q3 2025 and closing anticipated in Q4 2025, subject to regulatory and shareholder approvals. This combination leverages MindMaze's pioneering work and extensive R&D investment in neurotherapeutics, aiming to expand market reach and enhance growth potential. Relief’s chairman emphasized the transaction’s potential to create value for patients, clinicians, and shareholders by bringing a global pioneer in digital neurotherapeutics to the public markets.